The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Victoza (liraglutide), Tresiba (insulin degludec), Ryzodeg (insulin degludec/insulin aspart), IDegLira (liraglutide and insulin degludec), NovoSeven (recombinant human coagulation factor VIIa), NovoSeven RT (recombinant human coagulation factor VIIa), or Turoctocog alfa (third-generation recombinant coagulation factor VIII).

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Victoza (liraglutide), Tresiba (insulin degludec), Ryzodeg (insulin degludec/insulin aspart), IDegLira (liraglutide and insulin degludec), NovoSeven (recombinant human coagulation factor VIIa), NovoSeven RT (recombinant human coagulation factor VIIa), or Turoctocog alfa (third-generation recombinant coagulation factor VIII).

The present disclosure relates to non-metallic articles that can be burner shields having grease flow control and/or chemical resistance. The present disclosure also relates to glass-ceramic burner shields that can have grease flow control and/or chemical resistance, and preferably both.

The present disclosure relates to non-metallic articles that can be burner shields having grease flow control and/or chemical resistance. The present disclosure also relates to glass-ceramic burner shields that can have grease flow control and/or chemical resistance, and preferably both.

A glass material, includes the following components by weight percentage: 50-70% of SiO2; 3-15% of B2O3; 0.5-10% of TiO2; 1-12% of ZnO; 0.5-10% of Al2O3; 5-22% of Na2O+K2O, wherein B2O3/SiO2 is 0.06-0.26, and (TiO2+ZnO)/Al2O3 is 0.5-8.0. Through rational component design, the glass material features high light transmittance and excellent chemical stability, so as to be able to be applied in the field of photosensitive device packaging.

Disclosed herein are embodiments of a glass pharmaceutical package with unique composition. The pharmaceutical package includes a glass container with a first and second surface, the first surface being an outer surface of the glass container. The glass container is formed from a borosilicate glass composition, the glass composition including: at least 75 mol % SiO.sub.2; at least 10 mol % B.sub.2O.sub.3; and Al.sub.2O.sub.3 in an amount such that sum of SiO.sub.2, B.sub.2O.sub.3, and Al.sub.2O.sub.3 is at least 90 mol %. The glass container has at least two of the following: a hydrolytic resistance of class HGA 1 according to ISO 720:1985, a base resistance of class A1 or class A2 according to ISO 695:1991, and an acid resistance of class S2 or class S1 according to DIN 12116 (2001).

Disclosed herein are embodiments of a glass pharmaceutical package with unique composition. The pharmaceutical package includes a glass container with a first and second surface, the first surface being an outer surface of the glass container. The glass container is formed from a borosilicate glass composition, the glass composition including: at least 75 mol % SiO.sub.2; at least 10 mol % B.sub.2O.sub.3; and Al.sub.2O.sub.3 in an amount such that sum of SiO.sub.2, B.sub.2O.sub.3, and Al.sub.2O.sub.3 is at least 90 mol %. The glass container has at least two of the following: a hydrolytic resistance of class HGA 1 according to ISO 720:1985, a base resistance of class A1 or class A2 according to ISO 695:1991, and an acid resistance of class S2 or class S1 according to DIN 12116 (2001).

A glass for a pharmaceutical container of the present invention contains, as a glass composition, in terms of mol %, 70% to 85% of SiO.sub.2, 3% to 13% of Al.sub.2O.sub.3, 0% to 5% of B.sub.2O.sub.3, 0.1% to 18% of Li.sub.2O+Na.sub.2O+K.sub.2O, and 0% to 10% of MgO+CaO+SrO+BaO, in which a molar ratio (Li.sub.2O+Na.sub.2O+K.sub.2O)/Al.sub.2O.sub.3 is 1 or more and a molar ratio (Li.sub.2O+Na.sub.2O+K.sub.2O+MgO+CaO+SrO+BaO—Al.sub.2O.sub.3)/(SiO.sub.2+Al.sub.2O.sub.3) is 0.2 or less.

A glass for a pharmaceutical container of the present invention contains, as a glass composition, in terms of mol %, 70% to 85% of SiO.sub.2, 3% to 13% of Al.sub.2O.sub.3, 0% to 5% of B.sub.2O.sub.3, 0.1% to 18% of Li.sub.2O+Na.sub.2O+K.sub.2O, and 0% to 10% of MgO+CaO+SrO+BaO, in which a molar ratio (Li.sub.2O+Na.sub.2O+K.sub.2O)/Al.sub.2O.sub.3 is 1 or more and a molar ratio (Li.sub.2O+Na.sub.2O+K.sub.2O+MgO+CaO+SrO+BaO—Al.sub.2O.sub.3)/(SiO.sub.2+Al.sub.2O.sub.3) is 0.2 or less.

A glass tube for pharmaceutical containers and a manufacturing process for a glass tube are provided. The glass tubes are characterized by a homogenous and low alkali leachability on the inner surface.